UBLETAMIG
UNII CN0DU4MQE0
Substance Identification & Data
This profile provides standardized clinical and technical data for Ubletamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) CN0DU4MQE0.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3008247-27-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
CN0DU4MQE0
3008247-27-3
N/A
Detailed Substance Profile
Preferred Name
UBLETAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13410
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Ubletamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Ubletamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Ubletamig
Common Names & Synonyms
H-gamma4 heavy chain anti-MUC16 Homo sapiens (1-455) [VH (Homo sapiens IGHV3-49*04 (93.9%) -(IGHD) -IGHJ6*04 (90.0%) K120>R (121), CDR-IMGT [8.10.20] (26-33.51-60.99-118)) (1-129)-Homo sapiens IGHG4*01 nG4m(a) CH2 L92, 12-G4v5 h P10, 6-G4v7 CH2 delE1.4, P1.3, V1.2, A1.1 (CH1 (130-227), hinge 1-12 S10>P (237) (228-239), CH2 E1.4>del, F1.3>P (242), L1.2>V (243), G1.1>A (244), L92 (318) (240-348), CH3 (349-453), CHS (454-455)) (130-455)], (143-215')-disulfide with common L-kappa light chain Homo sapiens (1'-215') [V-KAPPA (Homo sapiens IGKV3-20*01 (100%) -IGKJ1*01 (100%), CDR-IMGT [7.3.9] (27'-33'.51'-53'.90'-98')) (1'-108') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (154'), V101 (192') (109'-215')]; H-gamma4 heavy chain anti-CD28 Homo sapiens (1''-448'') [VH (Homo sapiens IGHV4-59*01 (96.9%) -(IGHD) -IGHJ6*01 (100%), CDR-IMGT [8.7.16] (26''-33''.51''-57''.96''-111'')) (1''-122'')-Homo sapiens IGHG4*01 nG4m(a) CH2 L92, 12-G4v5 h P10, 6-G4v7 CH2 delE1.4, P1.3, V1.2, A1.1, 10-G4v8 CH3 R115, F116, P125(CH1 (123''-220''), hinge 1-12 S10>P (230'') (221''-232''), CH2 E1.4>del, F1.3>P (235''), L1.2>V (236''), G1.1>A (237''), L92 (311'') (233''-341''), CH3 H115>R (436''), Y116>F (437''), L125>P (446'') (342''-446''), CHS (447''-448'')) (123''-448'')], (136''-215''')-disulfide with common L-kappa light chain Homo sapiens (1'''-215''') [V-KAPPA (Homo sapiens IGKV3-20*01 (100%) -IGKJ1*01 (100%), CDR-IMGT [7.3.9] (27'''-33'''.51'''-53'''.90'''-98''')) (1'''-108''') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (154'''), V101 (192''') (109'''-215''')]; dimer (235-228'': 238-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa
Immunoglobulin G4 [237-proline,242-proline,243-valine,244-alanine,de-245-glycine], anti-(human mucin-16) (human monoclonal REGN5668 γ4-chain), disulfide with human monoclonal REGN5668 κ-chain, (235→228′),(238→231′)-bis(disulfide) with immunoglobulin G4 [230-proline,235-proline,236-valine,237-alanine,de-238-glycine,436-arginine,437-phenylalanine,446-proline] anti-(human CD28 antigen) (human monoclonal REGN5668 γ4-chain) disulfide with human monoclonal REGN5668 κ-chain
immunoglobulin (H-gamma4_L-kappa)_( H-gamma4_L-kappa), anti-[Homo sapiens MUC16 (mucin 16, MUC-16, cancer antigen 125, CA125)] and anti-[Homo sapiens CD28 (T cell specific surface glycoprotein CD28, TP44)], Homo sapiens monoclonal antibody, bispecific, bivalent (ubletamig)
ubletamig [INN]
